Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast
April 01 2019 - 8:00AM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that it will host a conference
call and live webcast at 8:30 a.m. Eastern
Time on Thursday, April 4, 2019, to provide an update on
portfolio strategic corporate initiatives and near-term clinical
and regulatory milestones for 2019 and to review the Company's
financial results for the year ended December 31, 2018.
To access the conference call via phone, dial (844) 831-3031
(domestic) or (443) 637-1284 (International). The conference ID
number for the call is 2172598. The live webcast can be accessed
under “Events & Presentations" in the Investor Relations
section of the Company's website at www.darebioscience.com.
Please log in approximately 5-10 minutes prior to the event to
register and to download and install any necessary software. To
access the replay, please call (855) 859-2056 (U.S.) or (404)
537-3406 (international). The conference ID number for the replay
is 2172598. The telephone and webcast replay will be available
until April 25, 2019.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women’s
sexual health, vaginal health, fertility, and contraception. The
company’s mission is to identify, develop and bring to market a
portfolio of novel, differentiated therapies that expand treatment
options, improve outcomes and facilitate convenience for women in
the areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential first-in-class
candidates in clinical development: Ovaprene®, a non-hormonal,
monthly contraceptive vaginal ring; Sildenafil Cream, 3.6%, a novel
cream formulation of sildenafil to treat female sexual arousal
disorder utilizing the active ingredient in Viagra®; DARE-BV1, a
unique hydrogel formulation of clindamycin phosphate 2% to treat
bacterial vaginosis via a single application; and DARE-HRT1, a
combination bio-identical estradiol and progesterone intravaginal
ring for hormone replacement therapy following menopause. To learn
more about Daré’s full portfolio of women’s health product
candidates, and mission to deliver novel therapies for women,
please visit www.darebioscience.com.
Daré may announce material information about its finances,
product candidates, clinical trials and other matters using its
investor relations website
(http://ir.darebioscience.com), SEC filings, press
releases, public conference calls and webcasts. Daré will use these
channels to distribute material information about the company, and
may also use social media to communicate important information
about the company, its finances, product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts on its investor relations
website (https://darebioscience.gcs-web.com/) and to follow
these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any
updates to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of the company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Alex GrayBurns McClellanagray@burnsmc.com212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:Amanda GuisbondCanale
Communicationsamanda@canalecomm.com781-405-8775
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024